An observational study in Primary Antiphospholipid Syndrome, sponsored by Cairo University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2018-10-24.
Sponsored by Cairo University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Antiphospholipid Syndrome with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Antiphospholipid Syndrome · Egypt.
Among the 10 studies in Antiphospholipid Syndrome with a site in Egypt, this one is the only one that started in 2017, is one of 4 observational ones, and was the 4th registered.
121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.
Browse Antiphospholipid Syndrome studies →5 of the 10 studies in Antiphospholipid Syndrome with a site in Egypt are open now. Recruiting first, the newest first:
New Valley University · Sites in Egypt
Ages 18+
New Valley University · Sites in Egypt
Ages 18+
New Valley University · Sites in Egypt
Ages 18+
Mohamed Sayed Abdelhafez · Sites in Egypt
Ages 20–38 · Women only
Assiut University · Sites in Egypt
Ages 18–55
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 38 Antiphospholipid Syndrome studies recruiting now, 14 (37%) set no upper age limit and 19 (50%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2017.
This study's enrollment of 50 is below the median of 156 across 50 observational studies indexed under Antiphospholipid Syndrome.
Median enrollment 100 across the 6 interventional studies, 76 across the 4 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 6 most frequent:
Cairo University is the lead sponsor of 4,941 studies on the registry; 1,457 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 2 studies filed under Antiphospholipid Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Antiphospholipid Syndrome with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07142239New Valley UniversityHematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome | 2026-12-30 |
| NCT07757789New Valley UniversityThrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study | 2027-09-25 |
| NCT07743242New Valley UniversityAutoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Antiphospholipid Syndrome with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Antiphospholipid antibody syndrome (APS) is an autoimmune disease characterized by systemic thrombosis and bad obstetric history. APS secondary to another medical disorder is the most common. Visual and ocular changes e.g. vaso-occlusive disease of retinal and choroidal vessels are found in patients with secondary APS. Patients with primary APS have also been reported to have ocular changes e.g. retinal vascular occlusion
The aim of our study to detect prevalence of ocular changes in women diagnosed with primary APS and correlation of these changes with adverse obstetric outcome. If a correlation is present, ocular findings in women with APS could be used in the future as a predictor for poor obstetric outcome.
Female patients (inpatient or outpatient) with primary antiphospholipid syndrome at Kasr-Alainy hospital (The Cairo University Hospital)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Informed consent 2. Detailed history emphasizing on a. obstetric complications related to antiphospholipid syndrome: i. Recurrent miscarriage ii. Fetal demise iii. Fetal growth restriction iv. Severe pre-eclampsia or eclampsia v. Placental insufficiency vi. Placental abruption b. Systemic vascular complications related to antiphospholipid syndrome: i. Arterial thrombosis ii. Venous thrombosis iii. Small-vessel thrombosis 3. Revision of diagnosis of primary antiphospholipid syndrome: 4. Exclusion of antiphospholipid syndrome secondary to SLE and other autoimmune diseases by: antinuclear (ANA), anti-Smith (Sm) and anti-double stranded DNA (dsDNA) antibodies. 5. Ophthalmological examination:
Diagnostic Test: Ophthalmological examination
Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
Also known as: slit lamp biomicroscopy, slit lamp exam
The incidence of Ocular changes in females with antiphospholipid syndrome
Number of participants with ocular findings detected by ophthalmological examination
Time frame: On the same day of enrollment into the study
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2017 to primary completion in Oct 2018, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.